Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug: Liraglutide

First Posted Date: 2017-06-01

Last Posted Date: 2022-12-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 720

Registration Number: NCT03172494

Locations: 🇨🇳
Novo Nordisk Investigational Site, Fuzhou, China

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: Placebo
Drug: semaglutide

First Posted Date: 2017-05-08

Last Posted Date: 2017-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 58

Registration Number: NCT03144271

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Canagliflozin
Drug: Placebo (canagliflozin)
Drug: Placebo (semaglutide)

First Posted Date: 2017-05-02

Last Posted Date: 2020-01-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 788

Registration Number: NCT03136484

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC9204-1706 A
Drug: Placebo

First Posted Date: 2017-03-30

Last Posted Date: 2018-10-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT03095807

Locations: 🇺🇸
Novo Nordisk Investigational Site, Baltimore, Maryland, United States

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2017-03-22

Last Posted Date: 2021-07-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 302

Registration Number: NCT03086330

Locations: 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec
Drug: Insulin glargine

First Posted Date: 2017-03-13

Last Posted Date: 2022-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1609

Registration Number: NCT03078478

Locations: 🇷🇸
Novo Nordisk Investigational Site, Nis, Serbia

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B

Interventions: Drug: ALPROLIX®
Drug: N9-GP

First Posted Date: 2017-03-09

Last Posted Date: 2023-05-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT03075670

Locations: 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: somapacitan
Drug: Norditropin

First Posted Date: 2017-03-09

Last Posted Date: 2020-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT03075644

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama, Kanagawa, Japan

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

Withdrawn

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide

First Posted Date: 2017-03-03

Last Posted Date: 2017-09-05

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT03070704

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide 0.5 mg
Drug: Sitagliptin
Drug: Semaglutide 1.0 mg
Drug: Semaglutide placebo 1.0 mg
Drug: Semaglutide placebo 0.5 mg
Drug: Sitagliptin placebo

First Posted Date: 2017-02-23

Last Posted Date: 2021-03-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 868

Registration Number: NCT03061214

Locations: 🇺🇦
Novo Nordisk Investigational Site, Lviv, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy